ImmunityBio Stock Has The Bull Case Changed After Going Concern Warning?
- ImmunityBio reported Q3 2026 revenue of US$48.84 million and a net loss of US$184.55 million, and management flagged substantial doubt about continuing as a going concern without fresh funding.
- While ANKTIVA secured new approvals in Israel and Europe and positive trial results, sequential softness in ANKTIVA sales highlighted execution and commercialization pressures on ImmunityBio’s core product story.
- Next, the focus shifts to how ImmunityBio’s investment narrative holds up against this wider loss and funding warning from Q3.
ImmunityBio Investment Narrative Recap
To stay invested in ImmunityBio, you need to believe the ANKTIVA bladder cancer franchise can support a broader immunotherapy platform while the firm works through heavy losses and funding pressure. Q3 2026 sharpened that tension. Revenue reached US$48.84 million, yet the net loss widened to US$184.55 million and management raised going concern doubts without new capital.
The near term story hinges on two moving parts: execution on ANKTIVA commercialization and label expansion as a key catalyst; and liquidity as the biggest risk. The analyst consensus Narrative on Simply Wall St leans on a much larger future revenue base. Recent results and the funding warning make the financing path a critical variable for that view.
The late stage QUILT 2.005 readout in BCG naive high grade non muscle invasive bladder cancer is the most relevant update here. ANKTIVA plus BCG met the primary endpoint against BCG alone, with quality of life maintained and no treatment related deaths reported. Management aims to file a supplemental BLA by year end 2026.
For you as a shareholder, that trial and the planned filing sit right beside the going concern flag. Progress in earlier stage NMIBC could support ANKTIVA’s role in standard urology practice and help the ImmunityBio story referenced in the analyst consensus Narrative on Simply Wall St. The catch is that clinical momentum does not remove the near term funding and cash burn risk.
ImmunityBio's current earnings are a loss of US$992.4 million, and analysts on Simply Wall St expect earnings to reach US$688.6 million by 2029. This implies an earnings swing of about US$1.68b. They also project revenue to reach US$1.5b by the same year and forecast yearly revenue growth of 106.7%.
Uncover why ImmunityBio's fair value indicates a 111% potential upside to its current price, which could close faster than many investors expect.
Exploring Other Perspectives
Some of the most optimistic ImmunityBio analysts focus on the BCG naive NMIBC catalyst. Before this earnings release, that group was pencilling in revenue of about US$2.4b and earnings near US$1.3b by 2029, far above consensus. You can treat those forecasts as one extreme and ask whether the latest loss and going concern warning might shift that optimism.
Explore 4 other ImmunityBio fair value estimates, including one that suggests potential upside of as much as 671% from the current price.
Form Your Own Verdict
Disagree with existing narratives? Extraordinary investment returns rarely come from following the herd, so consider conducting your own research.
- A great starting point for your ImmunityBio research is our analysis highlighting 3 key rewards and 2 important warning signs that could impact your investment decision.
- See our latest analysis for ImmunityBio. The report includes a comprehensive fundamental analysis summarized in a single visual, the Snowflake, making it easy to evaluate ImmunityBio's overall financial health at a glance.
Looking For More Investment Ideas Beyond ImmunityBio?
If ImmunityBio has sharpened your focus on how funding risk and future earnings expectations can reshape a story, it can help to compare it with other businesses that share some of those traits but show different financial profiles. The Simply Wall St Screener lets you filter the market by balance sheet strength, income potential, or perceived mispricing so you can build a wider watchlist that matches your own tolerance for risk and reward.
Here are a few angles you might want to explore next.
- If you want potential value opportunities with quality fundamentals, scan the market through 35 high quality undervalued stocks that may align better with your preferred risk profile.
- If capital preservation and stability matter most to you, focus on 30 resilient stocks with low risk scores that score well on financial resilience and business risk.
- If you prize financial strength as a buffer against funding concerns, filter for companies on the list of solid balance sheet and fundamentals (24 results) and compare their metrics with ImmunityBio's position.
Have feedback on this article? Concerned about the content? Get in touch with us directly. Alternatively, email editorial-team@simplywallst.com